Over the past few decades, biomarkers have become increasingly utilized as non-invasive tools in the early diagnosis and management of various clinical conditions. In perinatal medicine, the improved survival of extremely premature infants who are at high risk for adverse neurologic outcomes has increased the demand for the discovery of biomarkers in detecting and predicting the prognosis of infants with neonatal brain injury. By enabling the clinician to recognize potential brain damage early, biomarkers could allow clinicians to intervene at the early stages of disease, and to monitor the efficacy of those interventions. This review will first examine the potential perinatal biomarkers for neurologic complications of prematurity, specifically, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL) and posthemorrhagic hydrocephalus (PHH). It will also evaluate knowledge gained from animal models regarding the pathogenesis of perinatal brain injury in prematurity.
born each year (Hamilton et al., 2013) . Although improved neonatal intensive care and technological advances have allowed for increased survival of extremely premature infants, preterm birth accounts for over 75% of perinatal mortality and greater than 50% of perinatal and long-term morbidity (Berghella, 2010) .
The most common forms of central nervous system (CNS) injury in preterm infants are intraventricular hemorrhage (IVH), posthemorrhagic hydrocephalus (PHH) and periventricular leukomalacia (PVL). In extremely low birth weight infants weighing 500-999 g, IVH occurs in about 45% of neonates (Wilson-Costello et al., 2005) 
